Literature DB >> 15632797

Retention in publicly funded methadone maintenance treatment in two Western States.

Dennis Deck1, Matthew J Carlson.   

Abstract

This study examined individual and system characteristics associated with retention in methadone maintenance treatment among Medicaid-eligible adults in treatment for opiate use in Oregon and Washington. Logistic regression was used to examine the contributions of predisposing, need, and enabling characteristics on 365 day retention in methadone maintenance treatment. Older patients, patients with a history of methadone maintenance treatment, and persons with stable Medicaid eligibility had higher rates of retention than did patients with disabilities, polysubstance users, and those with an arrest record. In Oregon, which delivers methadone maintenance treatment through managed care, retention rose sharply from 28% to 51% between 1994 and 1998 and then leveled off. During the same time period, retention in Washington State grew from 28% to 34%. The higher rates of retention in Oregon, in part, can be explained by differences in service delivery influenced by financing. Faced with long waiting lists, Washington providers were more than twice as likely to administratively discharge patients for rule violations as their Oregon counterparts. Given the importance of retention, policies and practices that influence retention should be carefully considered. Because Medicaid eligibility has a dramatic impact on retention, policies that help extend eligibility or stabilize eligibility among individuals actively engaged in treatment should be carefully considered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15632797     DOI: 10.1007/BF02287327

Source DB:  PubMed          Journal:  J Behav Health Serv Res        ISSN: 1094-3412            Impact factor:   1.505


  40 in total

1.  Does retention matter? Treatment duration and improvement in drug use.

Authors:  Zhiwei Zhang; Peter D Friedmann; Dean R Gerstein
Journal:  Addiction       Date:  2003-05       Impact factor: 6.526

2.  Changes in criminal activity after entering methadone maintenance.

Authors:  J Bell; W Hall; K Byth
Journal:  Br J Addict       Date:  1992-02

3.  Treatment predictors of tenure in methadone maintenance.

Authors:  G W Joe; D D Simpson; R L Hubbard
Journal:  J Subst Abuse       Date:  1991

4.  Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency.

Authors:  H M Rhoades; D Creson; R Elk; J Schmitz; J Grabowski
Journal:  Am J Public Health       Date:  1998-01       Impact factor: 9.308

Review 5.  Treatment as harm reduction, defunding as harm maximization: the case of methadone maintenance.

Authors:  M Rosenbaum; A Washburn; K Knight; M Kelley; J Irwin
Journal:  J Psychoactive Drugs       Date:  1996 Jul-Sep

6.  A framework for the study of access to medical care.

Authors:  L A Aday; R Andersen
Journal:  Health Serv Res       Date:  1974       Impact factor: 3.402

7.  Revisiting the behavioral model and access to medical care: does it matter?

Authors:  R M Andersen
Journal:  J Health Soc Behav       Date:  1995-03

8.  Patient satisfaction, use of services, and one-year outcomes in publicly funded substance abuse treatment.

Authors:  M J Carlson; R M Gabriel
Journal:  Psychiatr Serv       Date:  2001-09       Impact factor: 3.084

9.  Changes in methadone treatment practices: results from a national panel study, 1988-2000.

Authors:  Thomas D'Aunno; Harold A Pollack
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

10.  Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-control study.

Authors:  G Serpelloni; M P Carrieri; G Rezza; S Morganti; M Gomma; N Binkin
Journal:  AIDS Care       Date:  1994
View more
  46 in total

1.  Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.

Authors:  Cheryl Teruya; Robert P Schwartz; Shannon Gwin Mitchell; Albert L Hasson; Christie Thomas; Samantha H Buoncristiani; Yih-Ing Hser; Katharina Wiest; Allan J Cohen; Naomi Glick; Petra Jacobs; Paul McLaughlin; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

2.  Superior methadone treatment outcome in Hmong compared with non-Hmong patients.

Authors:  Gavin Bart; Qi Wang; James S Hodges; Chris Nolan; Gregory Carlson
Journal:  J Subst Abuse Treat       Date:  2012-01-28

3.  Medicaid coverage and access to publicly funded opiate treatment.

Authors:  Dennis D Deck; Wyndy L Wiitala; Katherine E Laws
Journal:  J Behav Health Serv Res       Date:  2006-07       Impact factor: 1.505

4.  Outcomes for medicaid clients with substance abuse problems before and after managed care.

Authors:  Bentson H McFarland; Dennis D Deck; Lynn E McCamant; Roy M Gabriel; Douglas A Bigelow
Journal:  J Behav Health Serv Res       Date:  2005 Oct-Dec       Impact factor: 1.505

5.  Drug use, drug severity, and help-seeking behaviors of lesbian and bisexual women.

Authors:  Heather L Corliss; Christine E Grella; Vickie M Mays; Susan D Cochran
Journal:  J Womens Health (Larchmt)       Date:  2006-06       Impact factor: 2.681

6.  "It Ruined My Life": The effects of the War on Drugs on people who inject drugs (PWID) in rural Puerto Rico.

Authors:  R Abadie; C Gelpi-Acosta; C Davila; A Rivera; M Welch-Lazoritz; K Dombrowski
Journal:  Int J Drug Policy       Date:  2017-07-14

Review 7.  Using administrative data for longitudinal substance abuse research.

Authors:  Elizabeth Evans; Christine E Grella; Debra A Murphy; Yih-Ing Hser
Journal:  J Behav Health Serv Res       Date:  2008-08-05       Impact factor: 1.505

8.  Effect of eliminating behavioral health benefits for selected medicaid enrollees.

Authors:  K John McConnell; Neal T Wallace; Charles A Gallia; Jeanene A Smith
Journal:  Health Serv Res       Date:  2008-04-01       Impact factor: 3.402

9.  Why don't out-of-treatment individuals enter methadone treatment programmes?

Authors:  James A Peterson; Robert P Schwartz; Shannon Gwin Mitchell; Heather Schacht Reisinger; Sharon M Kelly; Kevin E O'Grady; Barry S Brown; Michael H Agar
Journal:  Int J Drug Policy       Date:  2008-09-20

10.  Patient-centered methadone treatment: a randomized clinical trial.

Authors:  Robert P Schwartz; Sharon M Kelly; Shannon G Mitchell; Jan Gryczynski; Kevin E O'Grady; Devang Gandhi; Yngvild Olsen; Jerome H Jaffe
Journal:  Addiction       Date:  2016-11-10       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.